Personalis (NASDAQ:PSNL) Given New $11.00 Price Target at HC Wainwright

Personalis (NASDAQ:PSNL) had its price objective increased by HC Wainwright from $9.00 to $11.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Needham & Company LLC restated a “buy” rating and set a $7.25 price target on shares of Personalis in a research report on Friday.

Personalis Stock Performance

PSNL stock opened at $5.75 on Friday. Personalis has a one year low of $1.12 and a one year high of $7.20. The company has a market capitalization of $406.23 million, a PE ratio of -3.42 and a beta of 1.88. The company’s 50 day moving average price is $4.35 and its two-hundred day moving average price is $3.85.

Personalis (NASDAQ:PSNL) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.31). Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. The business had revenue of $25.71 million during the quarter, compared to the consensus estimate of $20.67 million. During the same period in the prior year, the firm earned ($0.51) earnings per share. On average, research analysts predict that Personalis will post -1.41 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Barclays PLC lifted its holdings in Personalis by 45.4% in the 3rd quarter. Barclays PLC now owns 65,468 shares of the company’s stock worth $352,000 after buying an additional 20,444 shares during the period. Geode Capital Management LLC lifted its stake in Personalis by 20.0% in the third quarter. Geode Capital Management LLC now owns 498,470 shares of the company’s stock worth $2,683,000 after acquiring an additional 83,068 shares during the period. Jane Street Group LLC boosted its holdings in Personalis by 154.3% in the third quarter. Jane Street Group LLC now owns 164,281 shares of the company’s stock valued at $884,000 after acquiring an additional 99,671 shares in the last quarter. State Street Corp increased its position in Personalis by 34.5% during the 3rd quarter. State Street Corp now owns 175,142 shares of the company’s stock valued at $942,000 after purchasing an additional 44,900 shares during the period. Finally, Centiva Capital LP bought a new position in Personalis in the 3rd quarter worth $380,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.